C-terminally truncated interferon alpha variants
CA 2540884 C · Owner: Synthon Biopharmaceuticals B.V. · Inventors: Dickey, Lynn; Gasdaska, John; Cox, Kevin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides biologically active variants of human .alpha.- 2b- interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human .alpha.-2binterferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human .alpha.- 2b-interferon. The invention encompasses these biologically active variant .alpha.-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 16, 2004 and granted January 29, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 16, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 16, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.